Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common stock ("Common Shares")
-
Shares outstanding
-
213M
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
41.5M
-
Shares change
-
-3.15M
-
Total reported value, excl. options
-
$289M
-
Value change
-
-$36.3M
-
Put/Call ratio
-
1.01
-
Number of buys
-
74
-
Number of sells
-
-66
-
Price
-
$6.97
Significant Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) as of Q4 2021
174 filings reported holding OCUL - OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") as of Q4 2021.
OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.5M shares
of 213M outstanding shares and own 19.51% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (5.97M shares), SUMMER ROAD LLC (5.76M shares), BlackRock Inc. (5.12M shares), VANGUARD GROUP INC (4.08M shares), DELTEC ASSET MANAGEMENT LLC (2.1M shares), STATE STREET CORP (1.73M shares), CITADEL ADVISORS LLC (1.53M shares), GEODE CAPITAL MANAGEMENT, LLC (1.32M shares), EMERALD ADVISERS, LLC (1.06M shares), and EMERALD MUTUAL FUND ADVISERS TRUST (997K shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.